Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

79 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Topical Recombinant Human Nerve Growth Factor (Cenegermin) for Neurotrophic Keratopathy: A Multicenter Randomized Vehicle-Controlled Pivotal Trial.
Pflugfelder SC, Massaro-Giordano M, Perez VL, Hamrah P, Deng SX, Espandar L, Foster CS, Affeldt J, Seedor JA, Afshari NA, Chao W, Allegretti M, Mantelli F, Dana R. Pflugfelder SC, et al. Among authors: mantelli f. Ophthalmology. 2020 Jan;127(1):14-26. doi: 10.1016/j.ophtha.2019.08.020. Epub 2019 Aug 26. Ophthalmology. 2020. PMID: 31585826 Free article. Clinical Trial.
Phase I Trial of Recombinant Human Nerve Growth Factor for Neurotrophic Keratitis.
Bonini S, Lambiase A, Rama P, Filatori I, Allegretti M, Chao W, Mantelli F; REPARO Study Group. Bonini S, et al. Among authors: mantelli f. Ophthalmology. 2018 Sep;125(9):1468-1471. doi: 10.1016/j.ophtha.2018.03.004. Epub 2018 Apr 10. Ophthalmology. 2018. PMID: 29653861 Free article. Clinical Trial. No abstract available.
Alteration of galectin-3 in tears of patients with dry eye disease.
Uchino Y, Mauris J, Woodward AM, Dieckow J, Amparo F, Dana R, Mantelli F, Argüeso P. Uchino Y, et al. Among authors: mantelli f. Am J Ophthalmol. 2015 Jun;159(6):1027-1035.e3. doi: 10.1016/j.ajo.2015.02.008. Epub 2015 Feb 19. Am J Ophthalmol. 2015. PMID: 25703476 Free PMC article.
Ladarixin, an inhibitor of the interleukin-8 receptors CXCR1 and CXCR2, in new-onset type 1 diabetes: A multicentre, randomized, double-blind, placebo-controlled trial.
Piemonti L, Keymeulen B, Gillard P, Linn T, Bosi E, Rose L, Pozzilli P, Giorgino F, Cossu E, Daffonchio L, Goisis G, Ruffini PA, Maurizi AR, Mantelli F, Allegretti M. Piemonti L, et al. Among authors: mantelli f. Diabetes Obes Metab. 2022 Sep;24(9):1840-1849. doi: 10.1111/dom.14770. Epub 2022 Jul 4. Diabetes Obes Metab. 2022. PMID: 35589610 Free PMC article. Clinical Trial.
A Multicenter Phase 2 Randomized Controlled Study on the Efficacy and Safety of Reparixin in the Treatment of Hospitalized Patients with COVID-19 Pneumonia.
Landoni G, Piemonti L, Monforte AD, Grossi P, Zangrillo A, Bucci E, Allegretti M, Goisis G, Gavioli EM, Patel N, De Pizzol M, Pasedis G, Mantelli F. Landoni G, et al. Among authors: mantelli f. Infect Dis Ther. 2022 Aug;11(4):1559-1574. doi: 10.1007/s40121-022-00644-6. Epub 2022 May 26. Infect Dis Ther. 2022. PMID: 35618953 Free PMC article.
79 results